AbbVie today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for RINVOQ in…
QUÈ TREURE D'AQUEST ARTICLE:
- La Food and Drug Administration (FDA) ha aprovat RINVOQ® (upadacitinib) per al tractament d'adults amb colitis ulcerosa (CU) activa de moderada a severa que han tingut una resposta inadequada o intolerància a un o més bloquejadors del factor de necrosi tumoral (TNF).
- This FDA approval is the first indication for RINVOQ in….
- eTurboNews Els articles són només per a subscriptors.